Cannabidiphorol (CBDP) acts as a negative allosteric modulator at two distinct sites of cannabinoid receptor 1.
Recent research demonstrates that cannabidiphorol (CBDP) acts as a negative allosteric modulator at CB1 receptors through a novel dual-site mechanism. This finding suggests CBDP could potentially provide therapeutic cannabinoid system modulation without…
Effect of Cannabinol, THCV, and CBD on Voluntary Alcohol Consumption
This study investigates how cannabis compounds reduce alcohol consumption by influencing the endocannabinoid system. Cannabinol, tetrahydrocannabivarin, and cannabidiol were tested for their effects on voluntary alcohol intake. These findings highlight…
Cannabidiphorol (CBDP) as a Negative Allosteric Modulator at CB1
This article discusses minor cannabinoids CB1 receptors preclinical research focusing on cannabidiphorol (CBDP). CBDP acts as a negative allosteric modulator at two distinct sites of the CB1 receptor. Understanding this modulation is crucial for future…
Mira-55 Shows No THC- or Rimonabant-Linked CNS Side Effects in Preclinical Tests
Mira-55 represents a breakthrough in cb1 receptor modulation by avoiding CNS side effects linked to THC and rimonabant. This novel compound targets CB1 receptors for metabolic health benefits without psychoactive risks. Preclinical tests show promising…